These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20492877)

  • 1. [Psoriatic arthritis and etanercept].
    Pedraz J; Daudén E
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():26-34. PubMed ID: 20492877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
    Wong VK; Lebwohl MG
    Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
    Mease PJ
    Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriatic arthritis.
    Goupille P
    Joint Bone Spine; 2005 Dec; 72(6):466-70. PubMed ID: 16310398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New drugs and treatment strategies for rheumatoid arthritis].
    Fantini F
    Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biological agents in treatment of psoriatic arthritis].
    Lewicki M; Dutkiewicz B; Widuchowska M; Kucharz EJ
    Pol Merkur Lekarski; 2008 Jul; 25(145):97-100. PubMed ID: 18839626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-TNF alpha in the treatment of psoriatic arthritis].
    Claudepierre P; Wendling D; Cohen JD
    Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine blockers in psoriatic arthritis.
    Mease PJ
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii37-40. PubMed ID: 11890650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
    J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label dermatologic uses of anti-TNF-a therapies.
    Alexis AF; Strober BE
    J Cutan Med Surg; 2005 Dec; 9(6):296-302. PubMed ID: 16699906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis.
    Galadari H; Fuchs B; Lebwohl M
    Int J Dermatol; 2003 Mar; 42(3):231-7. PubMed ID: 12653923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
    Saad AA; Symmons DP; Noyce PR; Ashcroft DM
    J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
    Culy CR; Keating GM
    Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity.
    Massarotti M; Marasini B
    Int J Immunopathol Pharmacol; 2009; 22(2):547-9. PubMed ID: 19505409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment in psoriatic arthritis: our experience.
    Rioda WT; Adorni G
    Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.